Public deck

Aethlon Medical: the blood-filter high-risk thesis racing a $7 million cash clock

AEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matter.